IMC Retains Expression Analysis for Affymetrix GeneChip® Processing Services
News Jun 09, 2006
Expression Analysis, Inc. has entered into an agreement with IMC to provide isolation of genomic samples and Affymetrix microarray processing for samples from a clinical trial IMC is conducting on an award from the National Institute on Drug Abuse.
IMC received a grant last year from the National Institute on Drug Abuse to conduct a clinical trial utilizing their software, TeraGenomics, a high performance data warehousing solution for managing, analyzing and sharing Affymetrix GeneChip® microarray data to analyze the effectiveness of a compound used to treat addiction to methamphetamine.
After researching the market for a vendor to process the microarrays involved in the study, as well as some ancillary services, IMC decided on Expression Analysis.
"We felt Expression Analysis provided the expertise, capabilities and flexibility we required in a microarray processing partner because of the way we knew this project would evolve and change as it progressed," said Gregg Wright, Sr. VP Business Development and Solutions at IMC.
"Besides being price competitive, Expression Analysis demonstrated a willingness to work with us to solve process problems as they became apparent."
Expression Analysis will isolate genomic samples and analyze those on both gene expression and genotyping microarrays for IMC.
"We are very pleased that IMC has selected us to provide these services for their project," said Steve McPhail, President and CEO of Expression Analysis.
He continued, "We have built our business model around providing microarray services in a regulatory compliant environment, and focusing on communications and flexibility with clients in meeting their needs."
"The projects our clients bring us continue to validate our plan of supporting the value of microarray data generation in clinical trials."
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.